Compare LAC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | DCTH |
|---|---|---|
| Founded | 2023 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.2M | 578.4M |
| IPO Year | 2023 | 2015 |
| Metric | LAC | DCTH |
|---|---|---|
| Price | $1.67 | $21.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $5.07 | ★ $28.60 |
| AVG Volume (30 Days) | ★ 7.5M | 528.0K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.66 |
| Revenue Next Year | N/A | $20.12 |
| P/E Ratio | ★ N/A | $96.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.78 | $8.12 |
| 52 Week High | $6.96 | $21.84 |
| Indicator | LAC | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 81.79 |
| Support Level | N/A | $10.76 |
| Resistance Level | $2.22 | N/A |
| Average True Range (ATR) | 0.13 | 0.97 |
| MACD | 0.00 | 0.82 |
| Stochastic Oscillator | 1.85 | 95.13 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.